{"groups":[{"description":"In Treatment Crossover Period 1 participants first received pembrolizumab plus berahyaluronidase alfa subcutaneously (SC) for three 21-day cycles, followed by pembrolizumab intravenously (IV) for three 21-day cycles in Treatment Crossover Period 2. After completion of the Treatment Crossover Period, participants entered the Treatment Continuation Period where they received their preferred intervention for up to 17 21-day cycles (up to \\~1 year) for renal cell carcinoma (RCC) and melanoma, and for up to 35 21-day cycles (up to \\~2 years) for non-small cell lung cancer (NSCLC).","id":"FG000","title":"Arm A: Pembrolizumab (+) Berahyaluronidase Alfa SC →Pembrolizumab IV"},{"description":"In Treatment Crossover Period 1 participants first received pembrolizumab IV for three 21-day cycles, followed by pembrolizumab plus berahyaluronidase alfa SC for three 21-day cycles in Treatment Crossover Period 2. After completion of the Treatment Crossover Period, participants entered the Treatment Continuation Period where they received their preferred intervention for up to 17 21-day cycles (up to \\~1 year) for RCC and melanoma, and for up to 35 21-day cycles (up to \\~2 years) for NSCLC.","id":"FG001","title":"Arm B: Pembrolizumab IV→Pembrolizumab (+) Berahyaluronidase Alfa SC"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"4"},{"groupId":"FG001","numSubjects":"3"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}],"type":"Ongoing"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"71"},{"groupId":"FG001","numSubjects":"76"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"71"},{"groupId":"FG001","numSubjects":"0"}],"type":"Received Pembrolizumab (+) Berahyaluronidase Alfa SC"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"76"}],"type":"Received Pembrolizumab IV"},{"achievements":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"70"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"6"},{"groupId":"FG001","numSubjects":"6"}],"type":"NOT COMPLETED"}],"title":"Treatment Crossover Period 1: Cycles 1-3"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Lost to Follow-up"},{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Withdrawal by Subject"},{"reasons":[{"groupId":"FG000","numSubjects":"5"},{"groupId":"FG001","numSubjects":"7"}],"type":"Ongoing"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"70"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"70"}],"type":"Received Pembrolizumab (+) Berahyaluronidase Alfa SC"},{"achievements":[{"groupId":"FG000","numSubjects":"65"},{"groupId":"FG001","numSubjects":"0"}],"type":"Received Pembrolizumab IV"},{"achievements":[{"groupId":"FG000","numSubjects":"57"},{"groupId":"FG001","numSubjects":"59"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"8"},{"groupId":"FG001","numSubjects":"11"}],"type":"NOT COMPLETED"}],"title":"Treatment Crossover Period 2: Cycles 4-6"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}],"type":"Death"},{"reasons":[{"groupId":"FG000","numSubjects":"56"},{"groupId":"FG001","numSubjects":"56"}],"type":"Ongoing"}],"milestones":[{"achievements":[{"groupId":"FG000","numSubjects":"57"},{"groupId":"FG001","numSubjects":"59"}],"type":"STARTED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"0"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"57"},{"groupId":"FG001","numSubjects":"59"}],"type":"NOT COMPLETED"}],"title":"Treatment Continuation Period"}],"preAssignmentDetails":"147 participants were randomized to Treatment Arm A (n=71) or Treatment Arm B (n=76). Treatment Arms were defined per protocol as treatment sequence arms."}